Dr. Trey Boyd
Parkinson’s disease (PD) is the most common movement disorder and is second behind Alzheimer’s disease as neurodegenerative. Currently, no approved drug therapy is shown to slow progression and offer neuroprotection, cure, or reversal of neurodegeneration. Understanding the underlying cause of PD and the unique phenotypic variation of patients presents challenges in developing disease-modifying modalities. Various targets have been identified as critical areas to approach that can potentially change the course of disease progression in PD patients. Reaching these targets is achieved through multiple routes of administration such as pills and more invasive methods such as infusions, subcutaneous injections, and surgery.
Barnett K. Emerging Treatment Paradigms in the Management of Parkinson’s Disease. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2022; 4(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.